Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Tax Provision
Antengene Corporation Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Tax Provision
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Tax Provision
-¥488.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Tax Provision
-¥554.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-25%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Tax Provision
-¥498.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-9%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Tax Provision
-¥637.7m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Tax Provision
-¥100.2m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Tax Provision?
Tax Provision
0
CNY
Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Tax Provision amounts to 0 CNY.
You don't have any saved screeners yet